GSK Reorganizes Around Key R&D Areas As Lepore Exits

Therapy Area Research Units Created

The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.

GSK has unveiled a new R&D restructure to further increase productivity, creating dedicated teams for early-stage development in three key areas: vaccines and infectious diseases, respiratory/immunology and oncology.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Executives On The Move: Nine CEOs, Six CMOs And Three CFOs Among This Week’s Changes

11 Apr 2025

Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.

Executives On The Move: Five CMOs And CCOs Each And Four CFOs Among This Week’s Changes

08 Apr 2025

Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.

Executives On The Move: Harbour BioMed Gets New Chief Strategy Officer From BMS

28 Mar 2025

Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.

Executives On The Move: Two CMOs And Two CEOs and CFOs Each Among This Week’s Changes

10 Feb 2025

Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.

Samsung Bioepis Reevaluating Approach To Biosimilars

04 Apr 2025

• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.